Connecting Markets. Empowering People. Transforming Economies.
NiDCC

Insights

Insights and Intelligence

Home Insights and Intelligence

Intelligence for decisions, partnerships and market expansion.

Economic reporting from around the world, filtered to the sectors and policy areas our members build in — part of the same intelligence stream behind the Global Economic Outlook and NiDCC's market reports.

Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.

life_sciences — September 21, 2026, 5:12 PM · Barron's

Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.

Moderna's stock surged after proving the efficacy of its personalized cancer vaccine, intismeran autogene. The company is now preparing to present three abstracts for this mRNA cancer vaccine at the European Society for Medical Oncology's annual meeting, signaling a major upcoming test for the drug. Investors are keenly watching the next developments for this promising treatment.

Explore more
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026

life_sciences — September 21, 2026, 4:44 PM · Investing News Network

Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026

Moderna (NASDAQ: MRNA) announced that three abstracts for its investigational mRNA-based individualized neoantigen therapy, intismeran autogene, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026. These presentations will detail phase 3 study results for resected melanoma, phase I study results for resectable pancreatic ductal adenocarcinoma, and a phase 3 study of adjuvant intismeran autogene for high-risk stage I NSCLC. Moderna will also host a live webcast investor event during the congress to discuss these findings.

Explore more